[1]周欣,王永莉,汪妍.滋癸益经汤联合激素治疗对脾肾阳虚型卵巢早衰患者相关激素水平及预后的影响[J].陕西中医,2025,46(12):1628-1631,1641.[doi:DOI:10.3969/j.issn.1000-7369.2025.12.008]
　ZHOU Xin,WANG Yongli,WANG Yan.Effect of Zigui Yijing decoction combined with hormone therapy on hormone levels and prognosis in premature ovarian failure of spleen-kidney yang deficiency type[J].,2025,46(12):1628-1631,1641.[doi:DOI:10.3969/j.issn.1000-7369.2025.12.008]
点击复制

滋癸益经汤联合激素治疗对脾肾阳虚型卵巢早衰患者相关激素水平及预后的影响

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年12期
页码:
1628-1631,1641
栏目:
临床研究
出版日期:
2025-12-05

文章信息/Info

Title:
Effect of Zigui Yijing decoction combined with hormone therapy on hormone levels and prognosis in premature ovarian failure of spleen-kidney yang deficiency type
作者:
周欣; 王永莉; 汪妍
（无锡市中医医院治未病科，江苏 无锡 214071）
Author(s):
ZHOU Xin; WANG Yongli; WANG Yan
（Department of Preventive Medicine,Wuxi Traditional Chinese Medicine Hospital,Wuxi 214071,China）
关键词:
卵巢早衰; 滋癸益经汤; 脾肾阳虚; 激素; 月经; 戊酸雌二醇
Keywords:
Premature ovarian failure; Zigui Yijing decoction; Spleen-kidney yang deficiency; Hormone; Menstruation; Estradiol valerate
分类号:
R 711.75
DOI:
DOI:10.3969/j.issn.1000-7369.2025.12.008
文献标志码:
A
摘要:
目的：研究滋癸益经汤联合激素对脾肾阳虚型卵巢早衰患者相关激素水平以及预后的影响。方法：选取脾肾阳虚型卵巢早衰患者80例，分为对照组和研究组，各40例，对照组患者接受激素治疗，研究组患者接受激素联合滋癸益经汤治疗，共治疗3个月。比较两组患者治疗前后中医症候积分、卵巢功能以及血清激素（卵泡生成素、睾酮、黄体生成素）水平，并比较两组患者临床治疗疗效、治疗后月经复潮率以及治疗期间不良反应。结果：研究组患者治疗后总有效率高于对照组患者（95.00% 与75.00%，P<0.05）。治疗后，对照组患者中医症候积分和血清激素水平均降低（P<0.05），但均显著高于研究组患者（P<0.05）。两组患者治疗后卵巢体积、卵泡数量和卵巢血流收缩期峰值流速均升高，且研究组患者治疗后各项卵巢功能均高于对照组患者（P<0.05）。研究组患者治疗后半年内月经复潮>2次患者比例显著高于对照组患者（45.00% 与 15.00%，P<0.05），但两组患者治疗期间不良反应总发生率比较无统计学差异（40.00% 与32.50%，P>0.05）。结论：滋癸益经汤对脾肾阳虚型卵巢早衰具有显著的临床疗效，可显著改善患者性激素水平，提高患者卵巢功能和月经复潮率，安全有效。
Abstract:
Objective:The study investigates the effects of Zigui Yijing decoction combined with hormones on hormone levels and prognosis in premature ovarian failure of the spleen-kidney yang deficiency type.Methods:A total of 80 patients with ovarian failure of spleen and kidney yang deficiency were selected and divided into control group and study group,each with 40 cases,and the patients in the control group received hormone therapy,and the study group received hormone combined with Zigui Yijing decoction for a total of 3 months.Before and after treatment,we compared the TCM syndrome score,ovarian function,serum levels of follicle stimulating hormone,testosterone and luteinizing hormone,the efficacy of treatment,menstrual resurgence rate after treatment and adverse reactions.Results:For the total effective rate,the study group was higher than control group (95.00% vs 75.00%,P<0.05).After treatment,the TCM syndrome scores and serum FSH,LH and T hormone levels of the control groups were decreased (P<0.05),and all strongly higher than the study group (P<0.05).The ovarian volume,the number of follicles and peak systolic flow velocity of ovarian blood flow were increased in the two groups (P<0.05),and the ovarian functions was higher in the study group (P<0.05).After treatment,the proportion of patients in the study group who had two menstrual cramps > two times within six months (45.00% vs 15.00%,P<0.05),but there was no significant difference in the overall incidence of adverse reactions between the two groups during treatment (40.00% vs 32.50%,P>0.05).Conclusion:Zigui Yijing decoction has a significant clinical effect on premature ovarian failure with spleen-kidney yang deficiency,which can significantly improve the level of sex hormones in patients,improve ovarian function and menstrual resurgence rate in patients,and is safe and effective.

参考文献/References:

[1]HAMODA H,SHARMA A.Premature ovarian insufficiency,early menopause,and induced menopause[J].Best Pract Res Clin Endocrinol Metab,2024,38(1):101823.
[2]WANG Y,JIANG J,ZHANG J,et al.Research progress on the etiology and treatment of premature ovarian insufficiency[J].Biomed Hub,2023,8(1):97-107.
[3]DAI F,WANG R,DENG Z,et al.Comparison of the different animal modeling and therapy methods of premature ovarian failure in animal model [J].Stem Cell Res Ther,2023,14(1):135.
[4]COSTA G P O,FERREIRA-FILHO E S,SIMOES R D S,et al.Impact of hormone therapy on the bone density of women with premature ovarian insufficiency:A systematic review [J].Maturitas,2023,167:105-112.
[5]王慧源,吴洁.早发性卵巢功能不全的诊治进展[J].中国计划生育和妇产科,2024,16(6):7-10.
[6]SASSARINI J,LUMSDEN M A.Post cancer care in women with an increased risk of malignancy or previous malignancy:The use of hormone replacement therapy and alternative treatments [J].Best Pract Res Clin Endocrinol Metab,2024,38(1):101854.
[7]俞菊珍.女性尿液中邻苯二甲酸盐代谢物水平与卵巢早衰和生殖激素相关性研究[J].陕西医学杂志,2022,51(1):100-102，110.
[8]KALENGA C Z,METCALFE A,ROBERT M,et al.Association between the route of administration and formulation of estrogen therapy and hypertension risk in postmenopausal women:A prospective population-based study[J].Hypertension,2023,80(7):1463-1473.
[9]CHEN H,ZHANG G,PENG Y,et al.Danggui Shaoyao San protects cyclophosphamide-induced premature ovarian failure by inhibiting apoptosis and oxidative stress through the regulation of the SIRT1/p53 signaling pathway [J].J Ethnopharmacol,2024,323:117718.
[10]LIU J,YANG Y,HE Y,et al.Erxian decoction alleviates cisplatin-induced premature ovarian failure in rats by reducing oxidation levels in ovarian granulosa cells [J].J Ethnopharmacol,2023,304:116046.
[11]王桂云,刘慧萍,吴小兰,等.基于数据挖掘的卵巢早衰中医用药规律研究[J].中国中医药信息杂志,2023,30(9):40-46.
[12]中华中医药学会.卵巢早衰中西医结合诊疗指南[J].中国中西医结合杂志,2024，44(10):1167-1179.
[13]PANAY N.Premature ovarian insufficiency:Addressing the most controversial issues [J].Climacteric,2025,16:1-7.
[14]JIN J,RUAN X,HUA L,et al.Prevalence of metabolic syndrome and its components in Chinese women with premature ovarian insufficiency[J].Gynecol Endocrinol,2023,39(1):2254847.
[15]MO Y,SHANG A,WEI G,et al.Juvenile idiopathic arthritis and primary ovarian failure:A two-sample Mendelian randomization analysis in a mixed-gender cohort[J].Front Endocrinol,2024,15:1340993.
[16]ZHANG T,AIMUZI R,LU X,et al.Exposure to organophosphate esters and early menopause:A population-based cross-sectional study[J].Environ Pollut,2024,360:124684.
[17]LIU T,LIU X,ZHANG W,et al.The association of early menopause with increased risk of acute myocardial infarction:The interheart China study[J].J Women’s Health,2024,33(2):198-203.
[18]NASH Z,DAVIES M.Premature ovarian insufficiency [J].BMJ,2024,384:e077469.
[19]张瑞琪,饶远立,庞震苗,等.基于病程细分的中医优势治疗领域识别模型的理论验证:以卵巢早衰为例[J].广州中医药大学学报,2024,41(3):625-630.
[20]SOCHOCKA M,KARSKA J,PSZCZOLOWSKA M,et al.Cognitive decline in early and premature menopause[J].Int J Mol Sci,2023,24(7):6566.
[21]DANIEL J M,LINDSEY S H,MOSTANY R,et al.Cardiometabolic health,menopausal estrogen therapy and the brain:How effects of estrogens diverge in healthy and unhealthy preclinical models of aging[J].Front Neuroendocrinol,2023,70:101068.
[22]王华斌,李永文,丁勇利.维生素E联合激素补充疗法对卵巢早衰患者内分泌及生育功能的影响[J].中国煤炭工业医学杂志,2021,24(2):204-208.
[23]NADEEM M,NISA M U,BANGASH M H,et al.The comparative pharmaco- and histokinetics of the therapeutic dose of estradiol valerate and bromocriptine in common quails [J].Biomed Res Int,2022:5482895.
[24]胡菊,任涛涛,何文艳.激素替代疗法联合左归丸加减治疗肾阴虚卵巢早衰的临床效果研究[J].海南医学,2023,34(21):3069-3073.
[25]李格铬,崔晓萍,宜莉,等.卵巢早衰的中医研究进展[J].陕西中医,2023,44(4):534-537.
[26]HE Q,WAN S,JIANG M,et al.Exploring the therapeutic potential of tonic Chinese herbal medicine for gynecological disorders:An updated review[J].J Ethnopharmacol,2024,329:118144.
[27]王柳丁,樊雪鸣,申伟,等.张允岭从“脾肾并重”论治肌萎缩侧索硬化症经验[J].中医杂志,2023,64(20):2067-2070.
[28]尹晓岚,马祥雪,张北华,等.健脾中药复方治疗脾虚证作用机制研究现状与展望[J].世界科学技术-中医药现代化,2024,26(3):669-674.
[29]张佳莉,张岩.基于中医“肾-脑-骨”轴探讨女贞子及其活性成分的多脏器药理作用及潜在调控机制[J].上海中医药杂志,2024,58(5):1-8.
[30]尚子慧,侯亚迪,王利丽,等.山茱萸多糖的提取分离,化学结构及生物活性研究进展[J].中华中医药学刊,2024,42(5):233-239.
[31]夏心瑀,梁艳,董莉,等.从“肾-天癸-冲任-胞宫”生殖轴及“玄府理论”论卵巢早衰的针刺治疗[J].上海中医药大学学报,2024,38(4):87-91.
[32]杜嫦燕,关凤仪,罗宝玲.加减温经汤对脾肾阳虚型卵巢早衰相关激素水平及预后的影响[J].中华中医药学刊,2023,41(8):37-40.

相似文献/References:

[1]董若曦,朱小丹,张 越,等.淫羊藿及其主要成分在卵巢早衰治疗中的应用进展*[J].陕西中医,2019,(5):678.
[2]于晨媛.滋肾益坤清心汤联合地屈孕酮对卵巢早衰患者性激素水平及免疫指标的影响[J].陕西中医,2019,(6):740.
　YU Chenyuan..Effects of Zishen Yikun Qingxin decoction combined with progesterone on sex hormone levels and immune indexes in patients with premature ovarian failure[J].,2019,(12):740.
[3]高宁珂,王克华,闫 姝.免疫性卵巢早衰中西医诊疗进展[J].陕西中医,2021,(10):1480.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.041]
[4]李格铬,崔晓萍,宜 莉,等.卵巢早衰的中医研究进展[J].陕西中医,2023,(4):534.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.029]
　LI Gege,CUI Xiaoping,YI Li,et al.Research progress of Chinese medicine in premature ovarian failure[J].,2023,(12):534.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.029]
[5]王巢屹,周建惠,王 秋,等.名中医姜丽娟从“阴阳失衡”角度论治卵巢早衰常用对药撷萃[J].陕西中医,2025,46(5):685.[doi:DOI:10.3969/j.issn.1000-7369.2025.05.024]
　WANG Chaoyi,ZHOU Jianhui,WANG Qiu,et al.Professor JIANG Lijuan discusses the extraction of commonly used drugs for treating premature ovarian failure from the perspective of yin-yang imbalance[J].,2025,46(12):685.[doi:DOI:10.3969/j.issn.1000-7369.2025.05.024]
[6]黄柳倩,朱玲.岭南罗氏妇科朱玲辨治妇科疑难病常用药对拾萃[J].陕西中医,2025,46(12):1677.[doi:DOI:10.3969/j.issn.1000-7369.2025.12.019]
　HUANG Liuqian,ZHU Ling.Collection of professor ZHU Ling’s medicinal pairs commonly used in treatment of difficult gynecological diseases[J].,2025,46(12):1677.[doi:DOI:10.3969/j.issn.1000-7369.2025.12.019]

备注/Memo

备注/Memo:
国家自然科学基金资助项目（82305147）
更新日期/Last Update: 2025-12-08